
Lactiga Receives FDA ‘Rare Pediatric Disease’ Designation for Groundbreaking Mucosal Immunoglobulin Therapy for CVID
LCTG-001 on course to be the first FDA-approved biologic from human milk for pediatric patients with Common Variable Immunodeficiency.